Moreover, in an in vitro model of TNBC, dual treatment with Alpelisib/Ribociclib evoked an increased tumor immunogenicity due to overexpression of both HLA antigens and CTLA-4 on tumor cell-surface and decreased expression of PD-L1, which is known to be regulated by the PI3K pathway (95). Here, CD274 is linked to neoplasm.